HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide.

AbstractOBJECTIVE:
The aim of this study was to analyze both the constitutive and induced expression and function of double-stranded RNA (dsRNA; Toll-like receptor 3 [TLR-3], retinoic acid-inducible gene I [RIG-I], and melanoma differentiation-associated gene 5 [MDA5]) and single-stranded RNA (ssRNA; TLR-7) receptors in osteoarthritis (OA) and rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), by studying the transcription factors involved and the subsequent effects on antiviral interferon-β (IFNβ), the proinflammatory CXCL8 chemokine, and matrix metalloproteinase 3 (MMP-3). An additional goal was to study the effect of vasoactive intestinal peptide (VIP).
METHODS:
The expression of TLR-3, TLR-7, RIG-I, and MDA5 in cultured FLS was studied by reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), immunofluorescence, and Western blotting. Transcription factors were studied using the ELISA-based TransAM transcription factor kit. The expression of IFNβ, CXCL8 (interleukin-8), and MMP-3 was analyzed by RT-PCR and ELISA.
RESULTS:
FLS expressed TLR-3, TLR-7, RIG-I, and MDA5. The expression of TLR-3 and RIG-I was higher in RA FLS, while the expression of TLR-7 and MDA5 was higher in OA FLS. Stimulation with poly(I-C) induced the activation of IFN regulatory factor 3 (IRF-3), NF-κB, and activator protein 1 (AP-1) c-Jun as well as the subsequent production of IFNβ, CXCL8, and MMP-3. VIP reduced the activation of IRF-3 and the production of IFNβ in both OA and RA FLS. Imiquimod induced the activation of NF-κB, AP-1 c-Fos, and AP-1 c-Jun and the synthesis of CXCL8 and MMP-3. VIP significantly diminished MMP-3 production only in imiquimod-treated RA FLS.
CONCLUSION:
The results of this study revealed a prominent function of FLS in the recognition of both dsRNA and ssRNA, which may be present in the joint microenvironment. This study also advances the healing function of the endogenous neuroimmune peptide VIP, which inhibited TLR-3-, RIG-I-, MDA5-, and TLR-7-mediated stimulation of antiviral, proinflammatory, and joint destruction mediators.
AuthorsMar Carrión, Yasmina Juarranz, Selene Pérez-García, Rebeca Jimeno, José L Pablos, Rosa P Gomariz, Irene Gutiérrez-Cañas
JournalArthritis and rheumatism (Arthritis Rheum) Vol. 63 Issue 6 Pg. 1626-36 (Jun 2011) ISSN: 1529-0131 [Electronic] United States
PMID21337319 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 by the American College of Rheumatology.
Chemical References
  • Aminoquinolines
  • IRF3 protein, human
  • Interferon Inducers
  • Interferon Regulatory Factor-3
  • Interleukin-8
  • PLAAT4 protein, human
  • RNA, Double-Stranded
  • Receptors, Retinoic Acid
  • TLR3 protein, human
  • TLR7 protein, human
  • Toll-Like Receptor 3
  • Toll-Like Receptor 7
  • Transcription Factors
  • Vasoactive Intestinal Peptide
  • Interferon-beta
  • Matrix Metalloproteinase 3
  • IFIH1 protein, human
  • DEAD-box RNA Helicases
  • Interferon-Induced Helicase, IFIH1
  • Imiquimod
Topics
  • Aminoquinolines (pharmacology)
  • Arthritis, Rheumatoid (immunology)
  • Cells, Cultured
  • DEAD-box RNA Helicases (biosynthesis)
  • Fibroblasts (immunology)
  • Humans
  • Imiquimod
  • Interferon Inducers (pharmacology)
  • Interferon Regulatory Factor-3 (biosynthesis)
  • Interferon-Induced Helicase, IFIH1
  • Interferon-beta (biosynthesis)
  • Interleukin-8 (biosynthesis)
  • Matrix Metalloproteinase 3 (biosynthesis)
  • Osteoarthritis (immunology)
  • RNA, Double-Stranded (immunology)
  • Receptors, Retinoic Acid (biosynthesis)
  • Synovial Fluid (immunology)
  • Toll-Like Receptor 3 (biosynthesis)
  • Toll-Like Receptor 7 (biosynthesis)
  • Transcription Factors (metabolism)
  • Vasoactive Intestinal Peptide (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: